|
Volumn 12, Issue 4, 2016, Pages 188-189
|
Multiple sclerosis: Repurposing dopaminergic drugs for MS - The evidence mounts
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CABERGOLINE;
CHLORPROMAZINE;
DOPAMINE;
DOPAMINE RECEPTOR;
DOPAMINE RECEPTOR STIMULATING AGENT;
GAMMA INTERFERON;
HALOPERIDOL;
IMMUNOMODULATING AGENT;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 17;
METOCLOPRAMIDE;
PRAMIPEXOLE;
ROPINIROLE;
ROTIGOTINE;
CD4+ T LYMPHOCYTE;
CYTOKINE PRODUCTION;
DISEASE ACTIVITY;
DISEASE COURSE;
DOPAMINERGIC SYSTEM;
DRUG EFFICACY;
DRUG SAFETY;
EVIDENCE BASED MEDICINE;
HELPER CELL;
HUMAN;
HYPERPROLACTINEMIA;
IMMUNOPATHOGENESIS;
MULTIPLE SCLEROSIS;
NONHUMAN;
PARKINSON DISEASE;
PERIPHERAL BLOOD MONONUCLEAR CELL;
PRIORITY JOURNAL;
REGULATORY T LYMPHOCYTE;
REMISSION;
RESTLESS LEGS SYNDROME;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
|
EID: 84961964225
PISSN: 17594758
EISSN: 17594766
Source Type: Journal
DOI: 10.1038/nrneurol.2016.33 Document Type: Short Survey |
Times cited : (30)
|
References (10)
|